- Home
- ASGI vs CDXC Comparison
ASGI vs CDXC Comparison
Compare ASGI & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGI
- CDXC
- Stock Information
- Founded
- ASGI 2019
- CDXC 1999
- Country
- ASGI United States
- CDXC United States
- Employees
- ASGI N/A
- CDXC N/A
- Industry
- ASGI Investment Managers
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- ASGI Finance
- CDXC Health Care
- Exchange
- ASGI Nasdaq
- CDXC Nasdaq
- Market Cap
- ASGI 484.7M
- CDXC 546.9M
- IPO Year
- ASGI N/A
- CDXC N/A
- Fundamental
- Price
- ASGI $19.57
- CDXC $7.63
- Analyst Decision
- ASGI
- CDXC Strong Buy
- Analyst Count
- ASGI 0
- CDXC 2
- Target Price
- ASGI N/A
- CDXC $8.00
- AVG Volume (30 Days)
- ASGI 83.3K
- CDXC 3.0M
- Earning Date
- ASGI 01-01-0001
- CDXC 10-31-2024
- Dividend Yield
- ASGI 8.76%
- CDXC N/A
- EPS Growth
- ASGI N/A
- CDXC N/A
- EPS
- ASGI N/A
- CDXC 0.02
- Revenue
- ASGI N/A
- CDXC $91,668,000.00
- Revenue This Year
- ASGI N/A
- CDXC $18.64
- Revenue Next Year
- ASGI N/A
- CDXC $20.72
- P/E Ratio
- ASGI N/A
- CDXC $388.80
- Revenue Growth
- ASGI N/A
- CDXC 9.95
- 52 Week Low
- ASGI $14.96
- CDXC $1.32
- 52 Week High
- ASGI $18.55
- CDXC $7.85
- Technical
- Relative Strength Index (RSI)
- ASGI 48.96
- CDXC 75.32
- Support Level
- ASGI $19.12
- CDXC $6.80
- Resistance Level
- ASGI $19.80
- CDXC $7.67
- Average True Range (ATR)
- ASGI 0.28
- CDXC 0.58
- MACD
- ASGI 0.04
- CDXC 0.07
- Stochastic Oscillator
- ASGI 56.67
- CDXC 91.16
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.